October 26, 2026

Beyond Detection: How AI Is Reshaping Breast Imaging and Risk-Based Screening

Artificial intelligence in breast imaging is rapidly expanding beyond computer-aided cancer detection.

Baptist Health South Florida

October 16, 2026

Personalized Breast Cancer Screening: Moving Beyond Age-Based Algorithms

Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.

Baptist Health South Florida

October 15, 2026

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

Dana-Farber

October 15, 2026

2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC

Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.

Dana-Farber

October 14, 2026

Precision Treatment, Earlier Molecular Detection and De-escalation Transforming Breast Cancer Care

Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.

Baptist Health South Florida

October 13, 2026

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

Baptist Health South Florida

October 01, 2026

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.

Dana-Farber

September 23, 2026

Aurelio B. Castrellon, M.D., Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Medical Oncologist

Board-certified medical oncologist Aurelio B. Castrellon, M.D., has joined the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Health in Boynton Beach.

Baptist Health South Florida

September 15, 2026

Dana-Farber Research News 09.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 - 31.

Dana-Farber

September 03, 2026

Kriti Ahuja, M.D., Joins Baptist Health Wertheim Cancer Institute as a Breast Medical Oncologist

Baptist Health Wertheim Cancer Institute is pleased to welcome Kriti Ahuja, M.D., a board-certified medical oncologist specializing in breast cancer

Baptist Health South Florida